Pinnacle Wealth Management Advisory Group LLC Sells 221 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Pinnacle Wealth Management Advisory Group LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,041 shares of the biopharmaceutical company’s stock after selling 221 shares during the quarter. Pinnacle Wealth Management Advisory Group LLC’s holdings in Regeneron Pharmaceuticals were worth $742,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. Allworth Financial LP lifted its holdings in Regeneron Pharmaceuticals by 35.1% during the fourth quarter. Allworth Financial LP now owns 958 shares of the biopharmaceutical company’s stock worth $651,000 after acquiring an additional 249 shares during the period. Principal Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 43.9% during the 4th quarter. Principal Securities Inc. now owns 898 shares of the biopharmaceutical company’s stock worth $640,000 after purchasing an additional 274 shares during the period. Manchester Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 18 shares during the last quarter. ABC Arbitrage SA bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $1,510,000. Finally, Klingenstein Fields & Co. LP increased its holdings in Regeneron Pharmaceuticals by 1,083.7% during the fourth quarter. Klingenstein Fields & Co. LP now owns 6,806 shares of the biopharmaceutical company’s stock worth $4,848,000 after buying an additional 6,231 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.1 %

NASDAQ REGN opened at $673.60 on Monday. The stock’s 50-day simple moving average is $706.92 and its two-hundred day simple moving average is $896.16. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $74.02 billion, a price-to-earnings ratio of 17.60, a PEG ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $11.86 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th.

Analysts Set New Price Targets

REGN has been the topic of a number of research analyst reports. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Sanford C. Bernstein reduced their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Finally, Royal Bank of Canada dropped their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.